非小细胞肺癌胸腔积液与配对肿瘤组织中EGFR基因突变检测的比较

目的:探讨非小细胞肺癌胸腔积液与配对肿瘤组织标本中EGFR基因突变检测结果的一致性,评价胸腔积液标本检测EGFR基因突变的应用价值.方法:收集非小细胞肺癌患者胸腔积液与配对肿瘤组织样本72例,采用ARMS方法,检测样本中EGFR基因第18~21外显子突变情况.结果:细胞学样本和组织学样本中EGFR基因突变阳性率分别为48.61%和51.39%,两者差异无统计学意义(P>0.05),二者一致率为92.11%,不一致率为7.89%.结论:二者的一致率较高,恶性胸水可以作为无法获得肿瘤组织的晚期非小细胞肺癌EGFR基因检测的有效样本.

The study of detection EGFR gene mutation in non-small cell lung cancer tissue and matched pleural effusion

Objective:To investigate the consistency of EGFR gene mutations in pleural effusion of non-small cell lung cancer and matched tumor tissue samples,and to evaluate the application value of EGFR gene mutation in pleural effusion specimens.Methods:72 cases of non-small cell lung cancer patients with pleural effusion and matched tumor tissue samples were collected,using ARMS method to detect exon 18~21 mutations in EGFR gene.Results:The positive rates of EGFR gene mutation in cytology and histology samples were 48.61% and 51.39%,respectively,and the difference was not statistically significant (P>0.05).The consistency rate of the two groups was 92.11%,and the inconsistent rate was 7.89%.Conclusion:The consistency of the two patients was so high that the malignant pleural effusion can be used as a substitute for the detection of EGFR gene in patients with advanced non-small cell lung cancer.